Cryo-Cell International, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Income (Loss) per Common Share

Income (Loss) per Common Share

9 Months Ended

Aug. 31, 2019

Earnings Per Share [Abstract]

Income (Loss) per Common Share

Note 7 – Income (Loss) per Common Share

The following table sets forth the calculation of basic and diluted net income (loss) per common share:


	Three Months Ended				Nine Months Ended
	August 31, 2019		August 31, 2018		August 31, 2019		August 31, 2018
Numerator:
Net Income (Loss)	$	1,116,259	$	244,984	$	1,445,809	($	1,745,582	)

Denominator:
Weighted-average shares outstanding-basic		7,803,333		7,694,662		7,802,676		7,350,868
Dilutive common shares issuable upon exercise of stock options		641,904		681,013		627,575		—

Weighted-average shares-diluted		8,445,237		8,375,675		8,430,251		7,350,868

Net income (loss) per common share:
Basic	$	0.14	$	0.03	$	0.19	($	0.24	)

Diluted	$	0.13	$	0.03	$	0.17	($	0.24	)

For the three months ended August 31, 2019, the Company excluded the effect of 43,636 outstanding options from the computation of diluted earnings per share, as the effect of potentially dilutive shares from the outstanding stock options would be anti-dilutive. For the nine months ended August 31, 2019, the Company excluded the effect of 154,601 outstanding options from the computation of diluted earnings per share, as the effect of potentially dilutive shares from the outstanding stock options would be anti-dilutive.

For the three months ended August 31, 2018, the Company did not exclude any of the options from the computation of diluted earnings per share, as the effect of potentially dilutive shares from the outstanding stock options would be anti-dilutive. For the nine months ended August 31, 2018, the Company excluded the effect of all options from the computation of diluted earnings per share, as the effect of potentially dilutive shares from the outstanding stock options would be anti-dilutive.